Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

Phase 3 Completed 240 enrolled Panion & BF Biotech Inc. Shandong Weigao Panion Pharmaceutical Co. Ltd. · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of ferric citrate capsules for the treatment of hyperphosphatemia in patients with chronic kidney disease undergoing hemodialysis

Timeline

Start: 2019-06-19
Primary completion: 2021-02-20
Completion: 2021-02-20

Publications

Natale P, Green SC, Ruospo M, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ferric Citrate	Unknown	—	—
Comparator	sevelamer	Other / unclassified	—	—

Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

Summary

Timeline

Publications

Drugs

Indications